![Brown Pills](https://www.fdanews.com/ext/resources/test/Drug-Images/BrownPills.gif?t=1439844857&width=430)
Allergan, Endo Clarify Specialty Pharmacy Use Following Valeant Controversy
Allergan and Endo Pharmaceuticals are distancing themselves from controversy directed at Valeant, following a report by short-selling firm Citron alleging the pharmaceutical giant uses specialty pharmacies to inflate financial results.
Allergan says it doesn’t rely on specialty pharmacies to distribute its products, adding that roughly 3 percent of its U.S. branded sales — namely Botox (onabotulinumtoxinA) and Zenpep (pancrelipase) — are distributed through unaffiliated specialty pharmacies. Endo says about 3 percent of its 2015 projected revenue flows through independent specialty pharmacies.
Valeant has denied the Citron allegations, saying sales to Philidor Rx Services are not included in the consolidated financial results it reports publicly.